1 BTC
=
- USD
Atara Biotherapeutics, Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Atara Biotherapeutics, Inc
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Market Statistics
Trading Metrics
How to Buy ATRA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ATRA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesA securities class action lawsuit has been filed against Atara Biotherapeutics for allegedly making false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that undermined FDA approval prospects for tabelecleucel. Investors who purchased securities between May 20, 2024 and January 9, 2026 may be eligible for compensation. The lead plaintiff deadline is May 22, 2026.
A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026.
Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.
A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026. The lead plaintiff deadline is May 22, 2026.
The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.